Breaking News

NSF Expands Health Sciences Division

November 28, 2012

Skutnik, Engels, Langlais join global quality team

Janeen Skutnik will serve as partner with the Boston-based team of NSF-DBA. Ms. Skutnik will assist clients in complying with new and emerging quality regulations and global supply chain best practices, with a focus on quality systems and training for pharmaceutical, biotechnology, medical device and dietary supplement companies. She has more than 25 years of experience delivering training, auditing and consulting to the pharmaceutical and medical device industries. She has served in many leading quality assurance roles at both Pfizer and Merck, including director and team leader of Quality and Regulatory Policy at Pfizer.
Stephen Engels has been appointed principal consultant, responsible for overseeing operations in Switzerland, Italy, Germany and Austria. Mr. Engels will head quality management systems consulting, auditing and training activities. He has more than more than 25 years of experience in pharmaceutical quality and compliance roles. He has led quality assurance roles at Merck Serono in Switzerland and Italy, where he developed and implemented a global auditor qualification and training program as head of Quality Programs & Systems Development.
Peter Langlais has been appointed business development director for the NSF International Health Sciences Division, which includes NSF-DBA, NSF Pharmalytica, NSF Becker, NSF Reference Standards and NSF’s Dietary Supplements group. In his new role, he will help expand NSF’s services in biotechnology, pharmaceutical, reference standards, medical device and dietary supplement markets. Mr. Langlais has more than 24 years of sales and marketing experience. Previously, he led business development, marketing, sales, clinical diagnostics and global distributor networks for companies, including Tripos, IGEN International and Associates of Cape Cod, Inc.
“Stephen and Janeen’s innovative approach to quality assurance in the pharmaceutical and biotechnology sectors has made them both a widely sought resource for government officials and global pharmaceutical companies, and Peter’s experience working with global pharmaceutical and biotech companies will help NSF Health Sciences expand our services to new areas,” said Lori Bestervelt, Ph.D., NSF International’s chief science officer and senior vice president. “All three are valuable additions to the NSF Health Sciences team. Together, their combined 70 years of experience in pharmaceutical quality systems and global supply chain best practices will help NSF assist companies in meet their quality and compliance goals.”

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks